Published in Radiol Clin North Am on January 01, 2005
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
FDG PET/CT imaging in the diagnosis of osteomyelitis in the diabetic foot. Eur J Nucl Med Mol Imaging (2012) 1.60
Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. Br J Cancer (2010) 1.52
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res (2010) 1.13
Positron emission tomography imaging of prostate cancer. Amino Acids (2009) 1.11
FDG-PET/CT pitfalls in oncological head and neck imaging. Insights Imaging (2014) 1.00
Disseminated tuberculosis infection: a 'super' 18F-FDG PET/CT appearance. Eur J Nucl Med Mol Imaging (2009) 0.84
Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology. PLoS Negl Trop Dis (2015) 0.82
Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging (2008) 0.81
F-18 Fdg PET/CT Findings of a Patient with Takayasu Arteritis Before and After Therapy. Mol Imaging Radionucl Ther (2012) 0.79
FDG-PET/CT in large-vessel vasculitis: its diagnostic and follow-up role. Rheumatol Int (2009) 0.79
Optical imaging of bacterial infections. Clin Transl Imaging (2016) 0.77
Postsurgical atypical F-18 fluorodeoxyglucose positron emission tomography uptake. Clin Nucl Med (2009) 0.77
The role of F18-fluorodeoxyglucose positron emission tomography in identifying patients at high risk for lethal arrhythmias from cardiac sarcoidosis and the use of serial scanning to guide therapy. Int J Cardiovasc Imaging (2013) 0.77
Metabolic Pattern of Asymptomatic Hip-Prosthesis by 18F-FDG-Positron-Emission-Tomography. Iran J Radiol (2015) 0.76
Monitoring of systemic candidiasis by 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 0.75
Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in response monitoring of extra-pulmonary tuberculosis. Indian J Nucl Med (2016) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. Br J Radiol (2011) 0.75
Assessment of Therapy Response by (18)F-FDG PET/CT for a Patient with Cutaneous and Subcutaneous Mycobacterium Infection and Coexisting Lymphoma. Nucl Med Mol Imaging (2014) 0.75
cANCA-associated aortitis. Clin Kidney J (2012) 0.75
PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma. Medicine (Baltimore) (2016) 0.75
Differentiating osteoradionecrosis from nasopharyngeal carcinoma tumour recurrence using ⁹⁹Tcm-sestamibi SPECT/CT. Br J Radiol (2011) 0.75
A case of atypical giant cell arteritis diagnosed by positron emission tomography (PET). Clin Rheumatol (2008) 0.75
18F-FDG PET/CT is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report. Medicine (Baltimore) (2017) 0.75
The value of nuclear scans in cochlear implant infections. Eur Arch Otorhinolaryngol (2006) 0.75
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med (2007) 3.08
18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med (2002) 2.45
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med (2002) 2.05
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging (2007) 1.93
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr (2007) 1.92
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol (2013) 1.66
PET in the management of urologic malignancies. Radiol Clin North Am (2004) 1.62
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med (2002) 1.60
Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci (2006) 1.57
Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol (2015) 1.53
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med (2009) 1.51
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Is PET-CT the only option? Eur J Nucl Med Mol Imaging (2007) 1.48
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med (2007) 1.47
Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma (2004) 1.44
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging (2013) 1.44
Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med (2009) 1.44
Metabolic activity of the tongue in obstructive sleep apnea. A novel application of FDG positron emission tomography imaging. Am J Respir Crit Care Med (2014) 1.43
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat (2009) 1.42
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol (2009) 1.42
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med (2005) 1.38
When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging (2013) 1.37
Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging (2002) 1.37
Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med (2005) 1.33
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun (2009) 1.31
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med (2005) 1.30
Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol (2008) 1.30
Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med (2006) 1.28
Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat (2006) 1.27
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI-PET scanning. Neuroimage (2005) 1.26
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab (2007) 1.25
FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Mol Imaging (2008) 1.25
Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med (2002) 1.23
Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med (2007) 1.21
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med (2004) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med (2012) 1.18
Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med (2004) 1.16
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med (2011) 1.14
FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging (2009) 1.13
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging (2007) 1.13
A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med (2009) 1.12
FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med (2004) 1.11
Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol (2009) 1.11
Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am (2005) 1.10
Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med (2003) 1.10
Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT". J Nucl Med (2013) 1.10
Incidental inflammatory findings in nerves and in patients with neoplastic diseases evaluated by 18F-FDG-PET/CT. Hell J Nucl Med (2009) 1.10
Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin (2007) 1.10
Underestimated role of 18F-FDG PET for HCC evaluation and promise of 18F-FDG PET/MR imaging in this setting. J Nucl Med (2013) 1.09
18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol (2013) 1.09
Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging (2007) 1.08
PET/MR imaging: technical aspects and potential clinical applications. Radiology (2013) 1.08
18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med (2004) 1.08
Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Curr Opin Oncol (2005) 1.07
Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med (2010) 1.06
18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. Eur J Cancer (2013) 1.06
Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med (2007) 1.06
Retracted Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging. Eur J Nucl Med Mol Imaging (2013) 1.06
Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med (2007) 1.06
FDG uptake in intercostal muscles is an indicator of severe respiratory disease. Clin Nucl Med (2004) 1.05
A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging (2011) 1.04
18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med (2002) 1.04
PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med (2004) 1.04
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent. Int J Nanomedicine (2011) 1.03
FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med (2003) 1.03
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am (2005) 1.03
123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med (2005) 1.02
Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with chronic obstructive pulmonary disease. Clin Nucl Med (2005) 1.02
Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.02
Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med (2008) 1.02
F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med (2005) 1.02
Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am (2004) 1.02
Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol (2011) 1.01
Dynamic imaging in mild traumatic brain injury: support for the theory of medial temporal vulnerability. Arch Phys Med Rehabil (2002) 1.01
Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging (2007) 1.01
Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur J Nucl Med Mol Imaging (2002) 1.00